ContraFect Corporation Stock News

ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has informed ContraFect that it's good to move forward

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i

Use these technical indicators to profit with penny stocks The post Discover the Top Penny Stock Technical Indicators By Effectiveness appeared first on Penny Stocks to Buy, Picks, News and Informatio

ContraFect (NASDAQ: CFRX ) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange. That notice has to do with the continued listing of CFRX stock on the exchange.

Use these tips to invest in penny stocks right now The post The Future of Buying Penny Stocks: Trends for 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information

ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its

ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA